Moss Report on Sarcoma
Alternative & Conventional Sarcoma Treatments
The Moss Report on sarcoma begins with a discussion of the nature, symptoms, diagnosis and conventional treatment. This includes such topics as surgery, radiation therapy, chemotherapy, molecular therapy, and other new treatments.
It discusses markers used to detect the existence and progression of the disease, and useful methods for determining whether or not a patient will benefit appreciably from various treatments. The main body of this Moss Report contains comprehensive, up-to-date information on conventional, integrative, experimental, complementary, CAM, dietary, and alternative sarcoma treatments.
We also discuss innovative and alternative treatment centers for treating sarcoma, in the US and abroad.
This 500+ page report features a comprehensive discussion of the treatment and prevention of both soft tissue sarcoma and bone sarcomas, from the best techniques of surgery, radiation, chemotherapy and targeted therapy to the latest complementary and alternative (CAM) approaches. The Moss Report on Sarcoma also includes a discussion of how science is harnessing the immune system to fight these cancers through adoptive immunotherapy or CAR-T cell therapy, as well as the results of a relatively new drug, olaratumab (Lartruvo®) which, when combined with doxorubicin (Adriamycin®), nearly doubles the median overall survival in soft tissue sarcomas.
Every patient with either soft tissue or bone sarcoma and their loved ones should read this outstanding and newly revised Moss Report.
What’s New In Sarcoma Treatment
A discussion of an important phase 2 (non-randomized) study of patients with soft-tissue or bone sarcomas at 12 academic centers in the USA, led by the University of Texas M.D. Anderson Cancer Center, Houston. A study shows that olaratumab + doxorubicin is associated with increased overall survival of sarcoma patients., a special process of culturing white blood cells to attack cancer that also showed remarkable, but under-appreciated, results at M.D. Anderson and elsewhere.
James Allison, PhD, is the head of immunology at the University of Texas M.D. Anderson Cancer Center, Houston. While at the University of California, Berkeley, he invented an important new class of medications called “immune checkpoint inhibitors.” Allison is currently working on combining these medications with cancer-killing viruses, such as Newcastle Disease Virus (NDV) vaccines. These are already available at several foreign clinics.
One of the most significant advances of recent years has been the development and FDA approval of an anti-cancer virus vaccine, Reolysin® (pelareorep). The 2019 Moss Report discusses this new medicine and its associated clinical trials.
Discounts and Savings Available
Purchase both the E-Book and
Printed Moss Report and save $100.*
Purchase a Moss Report and
Schedule a Consultation and save $100.*
If you are a Medical Professional and refer patients to Moss Reports, click here find out more about our advocate program.
*Discounts applied when purchased together at check-out.
“I can’t tell you what a wealth of information we found and how helpful and informative the Report was. Thank you. My eyes were truly opened.” — L. C.
“Thank you very much. Your report is very helpful and comprehensive.” —B. S.
“We have received your report.. and sincerely appreciate your thoroughness and writing style.” —R. D.
“I have really been disappointed with radiation and chemotherapy and have been so glad that you steered me to more viable alternatives.” —W. V.
“Thanks for your help. Your service is a marvelous resource, tremendously helpful for those of us sifting through the masses of information that we have to go through in these really stressful situations.” — S. A.
Table of Contents
- A QUICK GUIDE TO CAM CANCER TREATMENTS
- GREEN LIGHT TREATMENTS: WELL RESEARCHED APPROACHES
- AMBER LIGHT TREATMENTS FOR CANCER: EFFICACY AND SAFETY STILL UNCLEAR
- RED LIGHT TREATMENTS: POORLY RESEARCHED (OR DOWNRIGHT DANGEROUS)
- CONVENTIONAL TREATMENT SECTION
- GRADES AND STAGES
- RADIATION THERAPY
- PREOPERATIVE RADIOTHERAPY
- INTRAOPERATIVE RADIOTHERAPY
- NEWER FORMS OF RADIATION THERAPY
- FDA APPROVED DRUGS
- NCCN RECOMMENDATIONS
- COMBINATION CHEMOTHERAPY
- OTHER DRUGS UNDER CONSIDERATION
- CHEMOTHERAPY OF SPECIFIC TUMORS
- NEOADJUVANT CHEMOTHERAPY
- MOLECULAR THERAPY
- ANTI-ANGIOGENIC AGENTS
- UTERINE SARCOMAS
- RADIATION THERAPY FOR CARCINOSARCOMA
- CHEMOTHERAPY FOR UTERINE CARCINOSARCOMA
- SURGERY FOR LEIOMYOSARCOMA
- RADIATION FOR LEIOMYOSARCOMA
- CHEMOTHERAPY FOR LEIOMYOSARCOMA
- ENDOMETRIAL STROMAL SARCOMAS
- ADOPTIVE IMMUNOTHERAPY
- SARCOMAS OF BONE
- FDA-APPROVED DRUGS FOR BONE CANCER
- CHEMOTHERAPY FOR METASTATIC DISEASE
- RELAPSED OR REFRACTORY OSTEOSARCOMA
- TOP SUPPLEMENTS (THE SHORT LIST)
- ANTI-CANCER PLAN ON A TIGHT BUDGET
- ANTI-CANCER RECIPES
- THE HALLMARKS OF CANCER
- A NEW MODEL FOR CANCER TREATMENT
- INNOVATIVE SURGERY
- INNOVATIVE RADIATION THERAPY
- INNOVATIVE CHEMOTHERAPY
- NAUSEA AND VOMITING
- MOUTH SORES (STOMATITIS)
- ZINC SULFATE
- NERVE PAIN
- HAIR LOSS
- PICKLE JUICE REMEDY
- CHEMOSENSITIVITY TESTING
- TARGETED THERAPIES
- PRECISION MEDICINE INITIATIVE
- ANTI-ANGIOGENESIS DRUGS
- MOLECULAR AND GENOMIC TESTING
- CIRCULATING TUMOR CELLS (CELLSEARCH)
- MONOCLONAL ANTIBODIES
- IMMUNE CHECKPOINT BLOCKADE (ICB)
- CANCER STEM CELLS (CSCS)
- DIETARY COMPOUNDS THAT KILL CANCER STEM CELLS (CSCS)
- PHYSICAL ACTIVITY AND EXERCISE
- FASTING AND THE KETOGENIC DIET
- A COST-FREE WAY TO PREVENT CANCER RECURRENCES
- CALORIC RESTRICTION
- PRACTICAL NOTES ON FASTING
- TOP TEN SUPPLEMENTS (THE EXPOSITION)
- FOOD AND CANCER PREVENTION
- VITAMINS, MINERALS & ANTIOXIDANTS
- THE CONCURRENT USE DEBATE
- CONCURRENT USE OF ANTIOXIDANTS AND RADIATION
- HERBS, SPICES AND BOTANICALS
- SOUND, LIGHT AND ELECTRICITY
- CANCER IMMUNOTHERAPY
- VIRAL THERAPY (ONCOLYTIC VIRUSES)
- DRUGS NEW AND OLD
- INNOVATIVE CANCER CLINICS
- FINDING AN INTEGRATIVE PHYSICIAN
- INTEGRATIVE ONCOLOGY DEPARTMENTS
- AMERICAN CLINICS
- INTERNATIONAL CLINICSSUPPLEMENTS AND SURGERY
- CAM AND FATIGUE
- POPULAR BUT UNLIKELY TREATMENTS